By avoiding funding Alzheimer's research, the government is cutting seniors' life spans
Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer's medication appears to slow cognitive decline by 35 percent. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.
Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer's medication appears to slow cognitive decline by 35 percent. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.
What's Your Reaction?
